摘要
Introduction: Periodontal disease (PD) is associated with increased risk of Alzheimer’s disease (AD), and the keystone periodontal pathogen Porphyromonas gingivalis (PG) has been implicated in this relationship. However, the mechanisms through which PG influences the central nervous system remain incompletely understood, particularly whether it directly translocates across the blood-brain barrier (BBB) or interacts with the cerebral vasculature to influence the perivascular environment and neuroinflammatory processes. SCPPPQ1, a naturally occurring protein produced by dento-gingival junction tissue, exhibits antimicrobial activity against PG and may provide a means of targeting periodontal infection at its source.
Methods: Two PG strains (W83 and ATCC 33277) were fluorescently labelled and administered intravenously (109 CFU in saline) to wild-type mice and rats. Animals were sacrificed after one hour. Bacterial distribution and localization in the cerebral vasculature and peripheral organs were investigated using fluorescence imaging, two-photon microscopy, and scanning electron microscopy (SEM). Ongoing studies will employ chronic PD models to investigate whether SCPPPQ1 treatment attenuates neurodegenerative changes and AD-relevant neuropathology, using in vivo neuroimaging techniques and array tomography approaches.
Results: Following intravenous administration, initial findings across four animals demonstrated the presence of PG in the cerebral vasculature and peripheral organs, including the liver and lungs. Two-photon microscopy and fluorescence imaging revealed focal bacterial accumulation, including large aggregates associated with cerebral vessels. SEM additionally identified PG within cerebral vessels and PG engulfed by peripheral immune cells in the liver and lung across animals. Further investigations are underway to determine whether PG can translocate beyond the BBB.
Conclusions: This investigation aims to elucidate how circulating PG interacts with the cerebral vasculature and perivascular environment, and how these interactions may contribute to AD-related pathology. Ongoing studies will evaluate whether targeting periodontal PG with SCPPPQ1 can mitigate neurovascular dysfunction and downstream neuropathological changes, potentially identifying a therapeutic strategy to reduce PD-associated contributions to AD progression.
